Industry News
Pharmaceutical Industry News
The company claims Botox should be…
The company claims Botox should be excluded from Inflation Reduction Act (IRA) pricing negotiations due to its status as a plasma-derived drug, which is meant to be excluded from IRA negotiations.
Alnylam achieved profitability for…
Alnylam achieved profitability for the first time in its history in 2025. But disappointing sales performance from Amvuttra in the closely watched ATTR-CM market and some expected turbulence in 2026 are weighing on its shares.
Supreme Group has added Broth to…
Supreme Group has added Broth to the mix of ad agencies it has cooked up in recent years. Backed by a private equity firm, Supreme has bought companies in quick succession to strengthen its marketing
One day after CSL revealed that it…
One day after CSL revealed that it had suddenly replaced its CEO, the company provided dismal financial figures that helped explain why it is undergoing the leadership change. In its half-year report, CSL said that
Belén Garijo’s appointment…
Belén Garijo’s appointment restores a woman CEO to the ranks of the top 10 Big Pharma companies.
U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine
The F.D.A.’s refusal to examine the company’s mRNA shot drew widespread criticism from doctors and was divisive within the agency.
OpenAI’s Biggest Challenge Is Turning Its A.I. Into a Cash Machine
The maker of ChatGPT hopes to triple its revenue in the coming year because it is planning to spend tens of billions of dollars. The clock is ticking.
For months now, all signs have…
For months now, all signs have pointed to a looming, steep dropoff in pharmas’ spending on traditional TV advertising. One brand that seems not to have gotten the memo, however, is Johnson & Johnson’s Tremfya.
Following a more than decade-long…
Following a more than decade-long legal back-and-forth over the generic drug carveout practice known as “skinny” labeling, GSK and Teva have put their dispute to bed, new court documents show.
Chinese prosecutors have brought…
Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs.
Gilead is expecting newly launched…
Gilead is expecting newly launched HIV PrEP Yeztugo to bring in $800 million in 2026 sales, a figure Mizuho Securities analysts described as "probably" conservative.
For all its success across a wide…
For all its success across a wide range of cancer types, Merck’s superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer. But now, 13 years
Acabo de regresar de China. Estados Unidos no está ganando
Si Estados Unidos quiere ser competitivo frente a China, tiene que poner orden en su economía.
F.D.A. Refuses to Review Moderna Flu Vaccine
The vaccine maker’s shots involve the successful Covid vaccines’ RNA technology. Health Secretary Robert F. Kennedy Jr. has broadly rejected it, canceling millions of dollars in research projects.
I Just Returned From China. We Are Not Winning.
If we are going to be competitive with China, we have to get our economic house in order.
Late Tuesday, Fujifilm…
Late Tuesday, Fujifilm Biotechnologies opened the doors to its expanded United Kingdom site in Teesside, capping off a 400 million pound (around $546 million) project that’s been in the works since late 2021. With the
PharmaEssentia will spend $46…
PharmaEssentia will spend $46 million to build a manufacturing facility in Puerto Rico. The move forms part of the Taiwanese biotech’s global expansion strategy to support demand for its rare blood disease treatment Besremi.
With Incyte set to lose patent…
With Incyte set to lose patent protection for its blood cancer standout, Jakafi, in late 2028, the company will have to rely more on its topical cream, Opzelura. In its fourth full year on the
A batch of untitled letters posted…
A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi.
The agreement includes mRNA…
The agreement includes mRNA vaccine supply and a technology transfer that allows Mexico's Laboratorios Liomont to produce Moderna's 2025-2026 COVID vaccine.